Shenzhen YHLO Biotech (SH:688575) Mei Ri Jing Ji Xin Wen·2026-01-08 13:33Core Viewpoint - The company, Yahui Long, has responded to inquiries from the Shanghai Stock Exchange regarding its strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd, clarifying the nature of the collaboration and its potential impact on the company's performance [1][2][5]. Group 1: Strategic Cooperation Details - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Starlink, focusing on product development, market promotion, and equity investment, with an estimated R&D investment of approximately 30 million yuan [1][2]. - The company plans to invest no more than 15 million yuan in Brain Machine Starlink, which represents a low percentage of its cash reserves and is not expected to significantly impact normal operations [3][4]. - The anticipated earliest revenue generation from this cooperation is not expected before November 2026, and the collaboration is currently in the early stages of development [2][3]. Group 2: Regulatory Response and Market Reaction - The Shanghai Stock Exchange issued a regulatory warning to Yahui Long for inaccurate and incomplete information disclosure regarding the cooperation, particularly concerning the technology path and product development stages [4][5]. - Following the initial announcement, Yahui Long issued a supplementary announcement clarifying that Brain Machine Starlink is focused solely on non-invasive technology, with many products still in early R&D or pre-clinical stages [2][4]. - The company's stock price rose by 6.52% on January 6, with trading volume increasing by 299%, prompting the exchange to emphasize the need for careful information disclosure to avoid misleading investors [5].